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Background. The contribution of the hemodialysis (HD) vascular access type to inﬂammation is unclear. Methods.W ec o n d u c t e d
a prospective observational study in an incident HD population. C-reactive protein (CRP), interleukin-6 (IL-6), and interferon-γ-
induced protein (IP-10) were measured before and at 6-time points after access placement for 1 year. Results. Sixty-four incident
HD patients were included (tunneled catheter (TC), n = 40, arteriovenous ﬁstula (AVF), n = 14, and arteriovenous graft (AVG),
n = 10). A mixed eﬀects model was performed to adjust for age, sex, race, coronary artery disease, diabetes mellitus, infections,
access thrombosis, initiation of HD, and days after access surgery. In comparison to AVFs, the presence of a TC was associated with
signiﬁcantly higher levels of CRP (P = 0.03), IL-6 (P = 0.07), and IP-10 (P = 0.03). The presence of an AVG was associated with
increases in CRP (P = 0.01) and IP-10 (P = 0.07). Conclusions. Patients who initiate HD with a TC or an AVG have a heightened
state of inﬂammation, which may contribute to the excess 90-day mortality after HD initiation.
1.Introduction
Themostrecent2009 USRDSreportobserved highﬁrst-and
second-month death rates after HD initiation [1]. The type
of HD vascular access is signiﬁcantly associated with risk of
death. The CHOICE study reported 50% higher mortality
rates in patients initiating HD with a TC as compared to
patients with an AVF. There was a trend toward higher mor-
tality rates (21% increased) in incident HD patients with
an AVG compared to those with an AVF; however this did
not achieve statistical signiﬁcance [2]. A recently published
Canadian study in 40,526 incident dialysis patients reported
an 80% higher 1-year mortality for HD patients with a TC
compared to PD patients and HD patients with an AVF or
AVG [3]. Potential reasons for these ﬁndings include the
higher rate of infection and sepsis associated with TCs, rela-
tive to AVFs; however the contribution of the vascular access
type, independent of infection, may also be a factor.
The prevalence of chronic inﬂammation is high (35–
65%) in the chronic kidney disease (CKD) and end-stage
renal disease (ESRD) populations [4–7]. Inﬂammation, as
assessed by using C-reactive protein (CRP) level, is a strong
predictor of all-cause and cardiovascular mortality in ESRD
patients[5–9].Multipleclinicalfactorsandintercurrentclin-
ical events may contribute to inﬂammation [10–14]. Stud-
ies analyzing the relationship between TCs and CRP levels
have reported contradictory ﬁndings. Although several small
studies reported an association between TCs and elevated
CRP levels and observed a substantial reduction in CRP after
TC removal with change of access to an AVF, these ﬁndings
were not reproduced in data collected for 1,826 prevalent
HD patients enrolled in the Hemodialysis (HEMO) Study
[15–20]. In fact, in the HEMO study, higher CRP levels
were inversely associated with TC use. The HEMO study
investigators did not ﬁnd a signiﬁcant change in CRP when
access was changed from a TC to an AVF or vice versa [20].
There are limited data on the longitudinal serial CRP values
andthe relationship to the vascularaccesstype in an incident
HD population and on the contribution of noninfected
arteriovenous grafts (AVG) to inﬂammation. Furthermore,2 International Journal of Nephrology
limited data exist for other inﬂammatory cytokines, such
as interleukin-6 (IL-6) and interferon-γ-induced protein
(IP-10). To investigate the role of the vascular access type
on serial inﬂammatory cytokines we studied a longitudinal
cohort of incident HD patients.
2.SubjectsandMethods
This is a prospective, observational study in a cohort of pre-
HD patients. This study was approved by the Committee of
Clinical Investigation at Monteﬁore Medical Center, (Proto-
col number 06-07-336). Patients with Stage-4 and -5 chronic
kidney diseases (CKD) receiving their initial HD vascular
access insertion were invited to participate. Patients were
recruited from 2 adult outpatient renal clinics, 8 private
nephrologypractices,andtheinpatientrenalpatientpopula-
tion at Monteﬁore Medical Center, Bronx, NY. Exclusion cri-
teria included the presence of an active inﬂammatory state:
infection, malignancy, connective tissue disease, HIV infec-
tion, organ transplant recipient, and current use of immune
modulating agents. The type of vascular access to be inserted
was determined by the patient’s physician. Patient data that
were recorded included age, race, sex, etiology of CKD, body
surface area, active tobacco use, diabetes mellitus (DM), and
a history of atherosclerotic diseases including cardiovascular
disease, myocardial infarction (MI), congestive heart failure
(CHF), peripheral vascular disease (PVD), and cerebral vas-
cular accident (CVA). A subjective global assessment (SGA)
was calculated for each patient at time of entry into the
study [21]. The conventional SGA is a three-tiered, semi-
quantitative scoring system based on the history and physical
examination and is commonly used in nephrology to quan-
tify the degree of malnutrition. All medications at time of
randomization were documented and include the use of
angiotensin-converting enzyme inhibitors (ACEI), angiot-
ensin receptor blockers (ARB), aspirin (ASA), nonsteroidal
anti-inﬂammatory agents (NSAID), erythropoiesis-stimu-
lating agents (ESA), vitamin D supplements, beta-blockers,
insulin, and the cholesterol-lowering statins. The date of HD
initiation, access thrombosis, interventional procedures, and
access survival were noted. Clinical events were recorded,
including infections, hospitalizations, and patient death.
Blood samples were drawn at baseline (within 1 month
prior to access surgery), then postsurgery on days 7, 30,
90, 180, 270, 365. In patients who initiated HD, samples
were drawn pre-HD. Samples were immediately centrifuged
(3000rpm for 10 minutes) and stored at −70 degrees. All
cytokine assays were performed at Vanderbilt University
Medical Center using cytometric bead array (Becton Dick-
insonTM, San Diego, Calif). The detection limits were as fol-
lows: CRP, 0.124mg/mL; IL-6, <2pg/mL; IP-10, 2.7pg/mL.
The intra-assay coeﬃcient of variation (CV) for CRP was
6%, IL-6 was 7.7%, and for IP-10 was 6.2%.
3.StatisticalAnalysis
Baseline laboratory data are presented as mean ± S.D, and all
cytokinevaluesarepresentedasthemedianandinterquartile
range (25th to 75th percentile). Univariate analyses were
Table 1: Patient demographic data. All cytokine values (CRP, IL-
6 and IP-10) are reported as the median, and all other lab data
are presented as the means ± S.D. Patients who received both a
TC and an AVF or AVG concomitantly were included in the TC
group. SGA: subjective global assessment, BMI: body mass index;
DM: diabetes mellitus; HTN: hypertension; CHF: congestive heart
failure; MI: myocardial infarction; CVA: cerebral vascular accident;
PVD: peripheral vascular disease; ESRD: end stage renal disease;
GN: glomerulonephritis; PCKD: polycystic kidney disease.
TC AVF AVG P value
N 40 14 10
Age in years 60 55 71 0.01
(±12) (±11) (±12)
Female sex 68% 14% 80% 0.005
Race/ethnicity
Black 46% 36% 70% ns
Hispanic 37% 57% 20%
Caucasian 12% 0 0
Other 5% 7% 10%
Co-morbid Diseases
HTN 96% 100% 100% ns
DM 64% 50% 100% ns
CHF 40% 29% 40% ns
MI 12% 29% 20% ns
CVA 20% 7% 30% ns
PVD 16% 0 10% ns
Hyperlipidemia 56% 64% 90% ns
BMI 28.0 28.6 31.0 ns
(±8.8) (±12.1) (±6.5)
SGA score ns
Low 28% 29% 0
Medium 36% 57% 60%
High 36% 14% 40%
Etiology of ESRD ns
DM 44% 36% 70%
HTN 12% 29% 30%
GN 0% 14% 0
PCKD 8% 7% 0
Other 29% 14% 0
Past malignancy 4% 7% 20% ns
Tobacco use ns
Current 4% 14% 0
Former 32% 21% 10%
performed using ANOVA (with Bonferroni correction) or
Chi-square analyses where appropriate. All cytokine val-
ues were analyzed using nonparametric statistical testing,
namely, the Kruskal-Wallis test. Patients who receive two
concomitantvascularaccessesinitially(TC/AVF,orTC/AVG)
were included in the TC group for all tables, ﬁgures, and
analyses. Signiﬁcance was determined at P = 0.05 (2-tailed).
Multivariate analyses for repeated measures were per-
formed using mixed eﬀects models, with CRP, IL-6, and IP-
10 as the dependent variables, and all were log transformed.
Covariatesthatwereincludedinthemodel(selectedapriori)International Journal of Nephrology 3
Table 2: Baseline laboratory data. All values are presented as the means ± S.D. eGFR: estimated glomerular ﬁltration rate; PTH: parathyroid
hormone; Hgb: hemoglobin, LDL: low-density lipoprotein.
TC AVF AVG P value
CRP (median, mg/L) 7.2 1.3 13.9 0.035
CRP >5 mg/L (%) 54% 23% 75% 0.04
IL-6 (median, pg/mL) 16.5 11.4 12.2 0.06
IP-10 (median, pg/mL) 222 148 289 ns
GFR (mL/min) 10 14 11 ns
(±7) (±6) (±4)
Albumin (g/dL) 3.5 3.7 3.3 ns
(±0.5) (±0.5) (±0.6)
Phosphorous (mg/dL) 6.1 5.1 5.6 ns
(±1.9) (±1.2) (±1.4)
Calcium (mg/dL) 8.0 8.5 8.7 ns
(±1.3) (−0.7) (±0.7)
PTH (pg/mL) 710 358 256 ns
(±990) (±283) (±134)
Hgb (g/dL) 9.1 10.4 10.1 0.009
(±1.5) (±1.0) (±2.0)
Ferritin (ng/mL) 328 250 255 ns
(±325) (±250) (±225)
Total cholesterol (mg/dL) 180 161 184 ns
(±56) (±67) (±39)
LDL cholesterol (mg/dL) 104 85 94 ns
(±47) (±51) (±26)
Hepatitis C Ab 13% 14% 10% ns
Table 3: Medications upon study entry. ASA: aspirin; ACEI/ARB:
angiotensin converting enzyme inhibitor or angiotensin receptor
blocker; ESA: erythropoietin stimulating agent.
TC AVF AVG P value
Statin 55% 50% 70% ns
ASA 28% 64% 70% 0.009
Beta-blocker 70% 79% 80% ns
Insulin 48% 43% 80% ns
Oral hypoglycemic 35% 0 20% 0.03
Phosphate binder 33% 21% 30% ns
Vitamin D 43% 43% 50% ns
ACEI/ARB 28% 50% 60% ns
ESA 38% 29% 90% 0.004
were age, sex, race, vascular access type, HD initiation, infec-
tion,vascularaccessthrombosis,cardiovasculardisease,DM,
and time period after vascular access surgery. Patients who
had a TC and a second arteriovenous access (arteriovenous
ﬁstula [AVF] or graft [AVG]) were classiﬁed as being in the
TC group for the mixed eﬀects models. A sensitivity analysis
was performed to compare the eﬀect of a TC alone versus an
AVF or AVG on inﬂammation (CRP, IL-6, IP-10).
4. Results
The study period was from August 2006 until April 2008.
Of the 79 patients who initially consented to participate in
the study, 14 patients did not show up for access surgery,
and 1 patient withdrew from the study 1 week after access
surgery. The mean followup for the remaining 64 patients
was 10 months (range 0.25–12 months).
The baseline patient demographic data are provided in
Table 1. The mean patient age was 61 years, and 52% were
women. The racial distribution of the study population was
48% African American, 39% Hispanic, 6% Caucasian, and
6% other race. The incidence of comorbid illnesses was: DM
69%, HTN 98%, CHF 38%, MI 17%, CVA 14%, PVD 11%,
hyperlipidemia 67%. There was a history of tobacco use in
28% (active use, 5%). The mean BMI was 29.2. The etiology
of ESRD was DM 48%, HTN 17%, unknown 16%, and
polycystic kidney disease 6%, representative of the general
ESRD population in the United States.
Thenumberofpatientsineachvascularaccessgroupwas
as follows: AVF, n = 14; AVG, n = 10; TC, n = 40 (24 with
a TC only, 11 with concomitant TC and AVF placement, and
5 with both TC and AVG placement). In the AVF group,
there was a signiﬁcantly higher representation of men, and
patients were of younger age, relative to the AVG and TC
groups. There were no other signiﬁcant diﬀerences in base-
line demographics between access groups.
Table 2 provides baseline laboratory data, and Table 3
lists the medications upon study entry. CRP, IL-6, and IP-10
levelsweresigniﬁcantlyhigheratbaselineinthepatientswith
a TC or AVG compared to patients with an AVF. None of the
other baseline laboratory values diﬀered between the access4 International Journal of Nephrology
Table 4: Mixed-eﬀects model for CRP (log transformation) including all time points throughout the study, (n = 662). In an adjusted
analysis, CRP levels positively correlated with the presence of a TC or AVG, history of coronary artery disease (CAD), and the time period 7
days after hemodialysis access insertion. There was an inverse correlation of CRP with male sex, and absence of infection. CRP: C-reactive
protein, TC: tunneled catheter, AVG: arteriovenous graft, AVF: arteriovenous ﬁstula, DM: diabetes mellitus, CAD: coronary artery disease,
HD: hemodialysis. Deﬁnitions: CRP: C-reactive protein, TC: tunneled catheter, AVG: arteriovenous graft, AVF: arteriovenous ﬁstula, DM:
diabetes mellitus, CAD: coronary artery disease, HD: hemodialysis.
Parameter Estimate 95% conﬁdence interval P
Lower Upper
Access type
AVF Ref.
TC 0.26 0.03 0.49 0.03
AVG 0.47 0.14 0.81 0.01
CAD (no) −0.54 −0.89 −0.19 <0.001
Sex (male) −0.28 −0.56 −0.01 0.04
Infection (no) −0.30 −0.55 −0.06 0.02
Age 0.00 −0.01 0.01 0.91
Race
Hispanic Ref.
African American 0.16 −0.11 0.43 0.23
Caucasian −0.11 −0.65 0.43 0.69
DM (no) −0.08 −0.36 0.21 0.60
HD (no) 0.01 −0.13 0.15 0.89
Access thrombosis (no) −0.08 −0.35 0.19 0.57
Number of days after access insertion
7 days 0.32 0.05 0.60 0.02
30 days −0.14 −0.40 0.11 0.26
90 days −0.09 −0.35 0.17 0.50
180 days −0.19 −0.43 0.06 0.13
270 days −0.06 −0.27 0.15 0.58
365 days Ref.
groups.PatientsintheAVGgrouphadthehighestuseofASA
and ESAs. Seven deaths occurred during the study period.
In those 7 patients the initial vascular access and cause of
death were as follows: AVF group (1 cardiac), AVG (2 sepsis,
1 cardiac death, 1 pneumonia), TC (1 sepsis, 1 pneumonia).
There were 9 patients whose initial vascular access was
a TC with a developing AVF, who subsequently had the TC
removed once the AVF was useable for HD. Although the
median CRP values declined after TC removal, this did not
achieve statistical signiﬁcance (TC/AVF: CRP 8.35mg/L ±
15.0, versus AVF alone: 3.16mg/L ± 1.8, P = 0.53). CRP data
wereavailableforonly2patientswhoseinitialvascularaccess
w a sa nA V Fw h ot h e nr e q u i r e daT C( A V F :1 3 . 5m g / Lv e r s u s
TC/AVF: 7.7mg/L). (Data were insuﬃcient for analysis.)
5.MultivariateAnalyses
Mixed eﬀects models (Tables 4, 5,a n d6) were performed for
CRP, IL-6, and IP-10, adjusting for the following covariates:
access type, coronary artery disease, sex, age, race, HD ini-
tiation, diabetes mellitus, infection, access thrombosis, and
number of days after access surgery. The adjusted models
take into account every cytokine measurement and the
corresponding vascular access type for each available period.
The presence of a TC was a signiﬁcant predictor of an
elevated CRP (P = 0.03) and IP-10 (0.03). IL-6 levels also
positively correlated with a TC, although this did not reach
statistical signiﬁcance, (P = 0.07). The presence of an AVG
also signiﬁcantly correlated with an elevated CRP (P = 0.01)
and with IP-10 (P = 0.07), although the latter did not reach
statistical signiﬁcance.
Additional predictors of an elevated CRP were a history
of CAD (P<0.001), female sex (P = 0.04), and the pres-
ence of infection (P = 0.02). Levels of CRP decrease over
time, with the highest value at 7 days after insertion com-
pared to the CRP values at 365 days (P = 0.02). IL-6 levels
signiﬁcantly correlated with infection (P = 0.02), and IP-10
levels were directly associated with diabetes mellitus (0.02),
male sex (0.01), and Hispanic ethnicity (0.04).
To compare the impact of TCs with other types of
vascular access on inﬂammation, we performed a sensitivity
analysis in patients with a TC exclusively (n = 24) and com-
pared them to the combined group of AVF/AVG (n = 24).
TCs remained a predictor of a higher CRP level, (estimate =
0.29, P = 0.055). There was no signiﬁcant association with
IL-6 and IP 10 levels in the sensitivity analysis.International Journal of Nephrology 5
Table 5: Mixed-eﬀects model for IL-6 (log transformation) including all time points throughout the study (n = 662). In an adjusted
analysis, IL-6 levels positively correlated with the presence of a TC, although this did not reach statistical signiﬁcance (P = 0.07). There
was an inverse correlation of IL-6 with absence of infection. IL-6: interleukin 6, TC: tunneled catheter, AVG: arteriovenous graft, AVF:
arteriovenous ﬁstula, DM: diabetes mellitus, CAD: coronary artery disease, HD: hemodialysis
Parameter Estimate 95% conﬁdence interval P
Lower Upper
Access type
AVF Ref.
TC 0.15 −0.01 0.32 0.07
AVG 0.12 −0.10 0.35 0.28
CAD (no) −0.17 −0.38 0.05 0.14
Sex (male) 0.08 −0.08 0.25 0.33
Infection (no) −0.24 −0.44 −0.04 0.02
Age 0.00 0.00 0.01 0.67
Race
Hispanic Ref.
African American 0.10 −0.06 0.27 0.21
Caucasian 0.02 −0.30 0.34 0.89
DM (no) −0.08 −0.25 0.08 0.32
HD (no) −0.01 −0.13 0.10 0.85
Access thrombosis (no) 0.09 −0.09 0.26 0.35
Number of days after access insertion
7d a y s 0 . 0 5 −0.16 0.27 0.61
30 days −0.12 −0.33 0.09 0.25
90 days −0.16 −0.37 0.04 0.12
180 days −0.24 −0.43 −0.05 0.01
270 days −0.14 −0.31 0.02 0.09
365 days Ref.
6. Discussion
This study is unique in that baseline cytokine values were
obtained before ﬁrst access placement and prior to HD ini-
tiation, which permitted assessing the degree of preexisting
inﬂammation for patients in each vascular access group and
comparing baseline cytokine values to those obtained at
multiple time periods after access insertion. The prospective
study design allowed for recording all intercurrent events,
which were included in the adjusted analysis. Because pa-
tients were enrolled upon initial access placement, we were
able to exclude the problem of preexisting inﬂammation
related to abandoned accesses. Finally, the association of
elevated CRP levels after initial AVG insertion adds to the
relative paucity of data on AVGs and inﬂammation in the
previously existing literature.
The ﬁndings of our study may also shade light on dis-
crepancies between the HEMO and other studies. First, the
Hemodialysis study (HEMO) included only patients who
were on HD therapy longer than 3 months, whereas our data
and others included incident HD patients. [18, 20]W e
observed, in an adjusted analysis, that CRP levels are
signiﬁcantly elevated only in the ﬁrst week following access
surgery,but,similartotheHEMOstudy, CRPlevelswerenot
elevatedat1monthorotherpointsthroughoutthefollowing
year. Secondly, in the HEMO study, AVFs and AVGs were
combined into one “AV access” group for the analysis, which
may have obscured diﬀerences between the AV access and
TC group and diﬀerences within the AV access group (AVFs
versus AVGs). We observed signiﬁcantly higher CRP values
associated with AVGs, not present with AVFs.
Our data are consistent with those of Goldstein et al.
who measured CRP in 73 incident HD patients (50 non-
infected TCs and 23 AVFs). The median CRPs at initi-
ation of HD were signiﬁcantly higher in the TC group
(44mg/L) versus the AVF group (5mg/L) (P<0.001) [18].
Unfortunately, patients with AVGs were not included in this
study. Other criticisms of this study were that only 2 CRP
measurements were taken over a 6-month period, other
inﬂammatory markers were not measured, and information
about comorbid illnesses was lacking [22]. Snaedal et al.
recently reported a strong association of comorbidity and
clinical events with inﬂammation in HD patients [23]. This
was a 3-month observational cohort study in prevalent HD
patients. Similar to the ﬁndings of the current study, these
investigators reported that a comorbidity score (including
ischemic heart disease) was among those factors that were
signiﬁcantly associated with variations in the CRP. They did
notﬁndasigniﬁcantassociationbetweenvascularaccesstype
and CRP in this prevalent HD population; however as was
the case in the HEMO study, AVF and AVGs were combined
into the same access group for the analysis.6 International Journal of Nephrology
Table 6: Mixed-eﬀects model for IP-10 (log transformation) including all time points throughout the study (n = 662). In an adjusted
analysis, IP-10 levels positively correlated with the presence of a TC and AVG, although the latter did reach statistical signiﬁcance, (P = 0.07).
IP-10 levels were also signiﬁcantly associated with male sex. There was an inverse correlation of IP-10 with DM and African American
or Caucasian race. IP-10: interferon-γ-induced protein, TC: tunneled catheter, AVG: arteriovenous graft, AVF: arteriovenous ﬁstula, DM:
diabetes mellitus, CAD: coronary artery disease, HD: hemodialysis
Parameter Estimate 95% Conﬁdence Interval P
Lower Upper
Access type
AVF Ref.
TC 0.26 0.03 0.49 0.03
AVG 0.30 −0.03 0.63 0.07
CAD (no) 0.17 −0.24 0.58 0.41
Sex (male) 0.43 0.12 0.74 0.01
Age 0.000 −0.01 0.01 0.65
Race
Hispanic Ref.
African American −0.30 −0.60 0.01 0.01
Caucasian −0.64 −1.25 −0.04 0.04
DM (no) −0.38 −0.70 −0.05 0.02
Infection (no) −0.14 −0.38 0.10 0.27
Access thrombosis (no) 0.10 −0.09 0.29 0.31
Number of days after access insertion
7d a y s 0 . 0 8 −0.17 0.34 0.52
30 days 0.06 −0.19 0.32 0.64
90 days 0.02 −0.22 0.26 0.85
180 days −0.10 −0.29 0.09 0.31
270 days −0.05 −0.21 0.11 0.51
365 days Ref.
There was a signiﬁcant direct association between female
sex and elevated CRP values in the present study, which was
observed in a multivariate model adjusting for diﬀerences
in vascular access type. This is in contradistinction to the
ﬁndings reported by Snaedal et al. in which female sex was
associated with lower CRP values, also a multivariate model
[23]. A third study by Goldstein et al. reported that CRP
values did not diﬀer between men and women [18]. The
relationship between gender and CRP levels is unclear and
requires further investigation.
Snaedel et al. reported widely ﬂuctuating CRP values in
68% of patients, indicating that frequent serial CRP mea-
surements are superior to a single measurement [23]. These
authorsalsostudiedotherinﬂammatorycytokines,including
plasma tumor necrosis factor-α (TNF-α) and interleukin-10
(IL-10), which were not found to be signiﬁcant predictors of
outcome.
A signiﬁcant association exists between elevated proin-
ﬂammatory cytokines and the presence of an AVG. We found
signiﬁcantly higher CRP levels associated with the presence
of AVGs (estimate = 0.47, P<0.001) and with TCs (esti-
mate = 0.26, P = 0.0 3 )r e l a t i v et oA V F s ,i na na d j u s t e d
analysis. These results diﬀer somewhat with those previously
reported by Movilli et al. [16] in that in our cohort of
incident HD patients CRP was highest in AVG patients. In
Movilli’s study, which included a cohort of infection-free
prevalent HD patients, TCs were associated with the highest
CRPvalues,althoughbothTCs(estimate =0.88,P = 0.0001)
and AVGs (estimate = 0.26, P = 0.043) were associated with
signiﬁcantly higher CRP levels than AVFs (adjusted analysis)
[16]. It is possible that “new” AVGs placed in incident HD
patients are associated with a period of peak inﬂammation
which dampens over time as the AVG endothelializes, as was
observed in the prevalent HD cohort.
The three-step hierarchy of access-associated inﬂamma-
tion (TC > AVG > AVF) reported in the Movilli study
closely mimics the relationship of mortality risk and vascular
access type in the CHOICE study [2, 15]. The choices for
healthyoutcomesincaringforESRD(CHOICE)studygroup
reported an association of mortality and vascular access
type in a cohort of incident HD patients. In this study, the
adjusted relative hazard of death was 1.5 (95% CI, 1.0 to
2.2) in patients using a TC and 1.2 (95% CI, 0.8 to 1.8) in
those with an AVG, relative to patients with an AVF [2]. A
recent study by Perl et al. also reported an adjusted, time-
dependent, relative hazard of death of 1.8 (95% CI, 1.6–
1.9) in incident HD patients with a TC compared to PD
patients or HD patients with an AVF/AVG [3]. As with the
HEMO study, because AVG and AVF are combined, the
exclusive eﬀect of AVGs with 1-year mortality is obscured.
Short of a randomized controlled trial, one may conclude
that it is possible that vascular access-induced inﬂammation,International Journal of Nephrology 7
independentofcomorbiditiesandintercurrentillnesses,may
be contributing to the excess mortality reported in TC and
AVG patients in the ﬁrst months of HD.
We also report that CKD patients whose future initial
vascular access is a TC or AVG have preexisting heightened
inﬂammatory state characterized by higher baseline CRP
levels, which is present prior to access surgery and HD initia-
tion, relative to those receiving AVFs. This was found despite
eﬀorts to exclude patients from the study with preexisting
inﬂammatorystates.PatientsintheTCandAVGgroupswere
older and consisted of more female and diabetic patients.
Furthermore, the subjective global assessment (SGA) scores
were higher at baseline in the TC and AVG groups. Patients
in the AVG group were also more anemic and had more ESA
use before access, possible reﬂecting a chronic inﬂammatory
state. Elevated baseline CRP values that are present in AVF
andTCpatientsmayhaveinﬂuencedtheCRPlevelsobserved
in these groups during the follow-up period. Ortega et al.
studiedCRPvaluesin66pre-HDpatientswhowerefollowed
up for 1 year [4]. The baseline CRP was 8.3mg/L, and 35%
of patients had an elevated CRP level (>6mg/L). High CRP
levels at baseline were predictive of a constant inﬂammatory
state at followup.
Although an association of TC use and higher ESA
requirements was reported by Goldstein et al. in a small co-
hort (n = 50), more recent data reported by the dialysis
outcomesandpracticepatternsstudy(DOPPS)inNovember
2010 did not ﬁnd a signiﬁcant association between catheter
use and ESA dosing in over 2,500 patients, although there
was a signiﬁcant association between higher CRP levels and
greater ESA dosing (presented at the American Society of
Nephrology Renal Week 2010). Data exploring the associa-
tion between ESA and TC use is not available in the present
study.
Lastly, dialysis vintage has not been shown to correlate
with inﬂammation in two previous studies or in the present
study [18, 23].
The major limitations of this study are the small size
of the trial and the limited follow-up period of 1 year. The
study was not powered using mortality as an outcome. Due
to the relative low mortality rate in our cohort, associations
between baseline cytokine values and mortality were not
observed. We attribute the low mortality due to the prede-
termined inclusion criteria for this study. In an attempt to
isolate the HD access from other potential mediators of
inﬂammationwechoseaselectpatientpopulation,excluding
unstable patients and those with active infection, autoim-
mune diseases, use of immune modulating medications, and
malignancy. A large study in an incident pre-HD population,
with a longer follow-up period, is needed to better elucidate
relationshipsbetweenthecontributionofindividualHDvas-
cular access types to noninfectious inﬂammation and pos-
sible excess mortality.
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